Open Medicine (Feb 2022)

A pan-cancer analysis of the oncogenic role of Holliday junction recognition protein in human tumors

  • Su Rong,
  • Huang Hechen,
  • Gao Xingxing,
  • Zhou Yuan,
  • Yin Shengyong,
  • Xie Haiyang,
  • Zhou Lin,
  • Zheng Shusen

DOI
https://doi.org/10.1515/med-2022-0423
Journal volume & issue
Vol. 17, no. 1
pp. 317 – 328

Abstract

Read online

Although cell-based or animal-based research evidence support the association of Holliday junction recognition protein (HJURP) with cancers, no pan-cancer investigation has been reported. The datasets of Gene Expression Omnibus database along with The Cancer Genome Atlas project were used to evaluate the expression of HJURP in various types of tumors. HJURP is overexpressed in a considerable number of cancers, and some changes in DNA methylation and genetic alterations are discovered in some types of tumors, such as kidney-related and adrenal gland-related tumors. Based on PrognoScan and gene expression profiling interactive analysis (GEPIA), the elevated expression of HJURP worsened the survival time of individuals with cancer. The biological general repository for interaction datasets (BioGRID) and The database for annotation, visualization and integrated discovery (DAVID) were used to establish the functional molecular network. It revealed that the cell cycle and p53 signaling pathway are the key molecular mechanisms that HJURP promotes carcinogenesis. The nomograms between HJURP and clinical pathological factors based on the Cox proportional hazards model showed a good prognostic performance in kidney carcinoma, hepatocellular carcinoma, and lung adenocarcinoma. Our first pan-cancer study provides a relatively profound insights into the oncogenic roles of HJURP across different tumors.

Keywords